Defined Human Clostridia Consortia Reverse Colitis via Dual Effects of Tryptophan Metabolites on Microbiota and Immunity

The authors investigated the therapeutic efficacy of two live biotherapeutic products, human Clostridia consortia 17-mix and 11-mix, by treating established colitis in murine models. Both LBPs exhibited therapeutic effects in T cell-mediated chronic colitis models induced by human microbiota and in pathobiont-driven gnotobiotic colitis models.